These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12416274)

  • 1. Drug class effects: definitions and practical applications.
    Soares I; Carneiro AV
    Rev Port Cardiol; 2002 Sep; 21(9):1031-42. PubMed ID: 12416274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
    Federman AD; Halm EA; Siu AL
    Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning].
    Sinagra G; Sabbadini G; Zecchin M; Di Lenarda A
    G Ital Cardiol (Rome); 2007 Sep; 8(9):559-67. PubMed ID: 17972425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for evidence in hypertension management: historical perspective.
    Moawad MA
    Ann Saudi Med; 2005; 25(5):367-74. PubMed ID: 16270757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Questionable group concept. How interchangeable are so-called analog drug preparations?].
    Wehling M
    MMW Fortschr Med; 2002 Nov; 144(46):56-8. PubMed ID: 12534084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders.
    Stöllberger C; Finsterer J
    Z Kardiol; 2003 Sep; 92(9):721-9. PubMed ID: 14508588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta-blockers and arterial hypertension. Evidence-based medicine or excessive perseverance?].
    Verdecchia P; Angeli F; Achilli P; Castellani C; Repaci S; Ambrosio G
    G Ital Cardiol (Rome); 2007 Sep; 8(9):552-8. PubMed ID: 17972424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
    Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
    Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drugs used in cardiovascular diseases and cytokines].
    Andrzejczak D; Górska D
    Wiad Lek; 2006; 59(3-4):232-7. PubMed ID: 16813270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.